The potential value of microRNA-145 for predicting prognosis in patients with ovarian cancer: A protocol for systematic review and meta-analysis.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
13 Aug 2021
13 Aug 2021
Historique:
received:
21
07
2021
accepted:
27
07
2021
entrez:
16
8
2021
pubmed:
17
8
2021
medline:
24
8
2021
Statut:
ppublish
Résumé
As an anticancer gene, microRNA-145 (miRNA-145) inhibits the growth, migration, and invasion of cancer cells, and inhibits tumorigenesis by targeting various genes that are abnormally expressed in tumors. However, whether miRNA-145 can be applied as a biomarker for potential prognosis of ovarian cancer still remains controversial. Therefore, this study further explored the prognostic value and mechanism of miRNA-145 in ovarian cancer through meta-analysis and bioinformatics analysis. Eligible studies were identified by searching the China National Knowledge Infrastructure, Chinese Biomedical literature Database, Chinese Scientific and Journal Database, Wan Fang database, PubMed, EMBASE, and Web of Science up to July 2021. Pooled hazard ratios with 95% confidence intervals for patient survival were calculated to investigate the effects of miRNA-145 on the prognosis of ovarian cancer. Survival curves of differential expression of miRNA-145 were analyzed by Oncomir. The target genes of miRNA-145 were predicted by miRTARbase and Diana-Tarbase V7.0 database. Enrichr database was applied to analyze the target genes by gene ontology and Kyoto Encyclopedia of Genes and Genomes pathways. Protein-protein interaction network of target genes was constructed from STRING database. Cytoscape software was used to screen the hub genes to meet the requirements. The Gene Expression Profiling Interactive Analysis database was applied to analyze the survival outcomes of hub genes. The results of this meta-analysis would be submitted to peer-reviewed journals for publication. This study provides high-quality evidence to support the relationship between miRNA-145 expression and ovarian cancer prognosis. Through bioinformatics analysis, we further explored the mechanism of miRNA-145 in ovarian cancer and related pathways.
Sections du résumé
BACKGROUND
BACKGROUND
As an anticancer gene, microRNA-145 (miRNA-145) inhibits the growth, migration, and invasion of cancer cells, and inhibits tumorigenesis by targeting various genes that are abnormally expressed in tumors. However, whether miRNA-145 can be applied as a biomarker for potential prognosis of ovarian cancer still remains controversial. Therefore, this study further explored the prognostic value and mechanism of miRNA-145 in ovarian cancer through meta-analysis and bioinformatics analysis.
METHODS
METHODS
Eligible studies were identified by searching the China National Knowledge Infrastructure, Chinese Biomedical literature Database, Chinese Scientific and Journal Database, Wan Fang database, PubMed, EMBASE, and Web of Science up to July 2021. Pooled hazard ratios with 95% confidence intervals for patient survival were calculated to investigate the effects of miRNA-145 on the prognosis of ovarian cancer. Survival curves of differential expression of miRNA-145 were analyzed by Oncomir. The target genes of miRNA-145 were predicted by miRTARbase and Diana-Tarbase V7.0 database. Enrichr database was applied to analyze the target genes by gene ontology and Kyoto Encyclopedia of Genes and Genomes pathways. Protein-protein interaction network of target genes was constructed from STRING database. Cytoscape software was used to screen the hub genes to meet the requirements. The Gene Expression Profiling Interactive Analysis database was applied to analyze the survival outcomes of hub genes.
RESULTS
RESULTS
The results of this meta-analysis would be submitted to peer-reviewed journals for publication.
CONCLUSION
CONCLUSIONS
This study provides high-quality evidence to support the relationship between miRNA-145 expression and ovarian cancer prognosis. Through bioinformatics analysis, we further explored the mechanism of miRNA-145 in ovarian cancer and related pathways.
Identifiants
pubmed: 34397934
doi: 10.1097/MD.0000000000026922
pii: 00005792-202108130-00068
pmc: PMC8360411
doi:
Substances chimiques
Biomarkers, Tumor
0
MIRN145 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e26922Subventions
Organisme : hainan health and family planning industry scientific research project
ID : 18A200006
Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Xia L, Wang Y, Cai S, Xu M. DGAT1 expression promotes ovarian cancer progression and is associated with poor prognosis. J Immunol Res 2021;2021:01–10.
Karimi-Zarchi M, Mortazavizadeh SMR, Bashardust N, et al. The clinicopathologic characteristics and 5-year survival rate of epithelial ovarian cancer in Yazd, Iran. Electron Physician 2015;7:1399–406.
Tanaka Y, Terai Y, Tanabe A, et al. Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer. Cancer Biol Ther 2011;11:50–7.
Lee E, Ito K, Zhao Y, Schadt EE, Irie HY, Zhu J. Inferred miRNA activity identifies miRNA-mediated regulatory networks underlying multiple cancers. Bioinformatics 2016;32:96–105.
Kim TH, Jeon HG, Jeong BC, et al. Development of a new nomogram to predict insignificant prostate cancer in patients undergoing radical prostatectomy. Scand J Urol 2017;51:27–32.
Yu F, Liu J, Dong W, Xie J, Zhao X. The diagnostic value of miR-145 and miR-205 in patients with cervical cancer. Am J Transl Res 2021;13:1825–32.
Huang ZG, Sun Y, Chen G, et al. MiRNA-145-5p expression and prospective molecular mechanisms in the metastasis of prostate cancer. IET Syst Biol 2021;15:01–13.
Zeinali T, Karimi L, Hosseinahli N, et al. Overexpression of miRNA-145 induces apoptosis and prevents proliferation and migration of MKN-45 gastric cancer cells. EXCLI J 2020;19:1446–58.
Lv P, Zhang Z, Hou L, et al. Meta-analysis of the clinicopathological significance of miRNA-145 in breast cancer. Biosci Rep 2020;40:BSR20193974.
Xu WX, Liu Z, Deng F, et al. MiR-145: a potential biomarker of cancer migration and invasion. Am J Transl Res 2019;11:6739–53.
Guo L, Cai X, Hu W, et al. Expression and clinical significance of miRNA-145 and miRNA-218 in laryngeal cancer. Oncol Lett 2019;18:764–70.
Garrido MP, Torres I, Avila A, et al. NGF/TRKA decrease miR-145-5p levels in epithelial ovarian cancer cells. Int J Mol Sci 2020;21:7657.
Zhou J, Zhang X, Li W, Chen Y. MicroRNA-145-5p regulates the proliferation of epithelial ovarian cancer cells via targeting SMAD4. J Ovarian Res 2020;13:54.
Zuberi M, Mir R, Khan I, et al. The promising signatures of circulating microRNA-145 in epithelial ovarian cancer patients. MicroRNA 2020;9:49–57.
Liang H, Jiang Z, Xie G, Lu Y. Serum microRNA-145 as a novel biomarker in human ovarian cancer. Tumour Biol 2015;36:5305–13.
Lin P, Zou C. Expression and clinical significance of microRNA-145 in epithelial ovarian cancer tissues and cell lines. J Nanjing Med Univ 2018;11:1528–32.
Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:g7647.
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:01–16.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.
Zhang Q, Jin Y, Li X, et al. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphisms and risk of venous thromboembolism – a meta-analysis and systematic review. Vasa 2020;49:141–6.
Lewis SJ, Zammit S, Gunnell D, Smith GD. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.
Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455–63.
Vlachos IS, Paraskevopoulou MD, Karagkouni D, et al. DIANA-TarBase v7.0: indexing more than half a million experimentally supported miRNA:mRNA interactions. Nucleic Acids Res 2015;43:D153–159.
Cui L, Kwong J, Wang CC. Prognostic value of circulating tumor cells and disseminated tumor cells in patients with ovarian cancer: a systematic review and meta-analysis. J Ovarian Res 2015;8:38.
Yousefi M, Rajaie S, Keyvani V, Bolandi S, Hasanzadeh M, Pasdar A. Clinical significance of circulating tumor cell related markers in patients with epithelial ovarian cancer before and after adjuvant chemotherapy. Sci Rep 2021;11:10524.
Letelier P, García P, Leal P, et al. miR-1 and miR-145 act as tumor suppressor microRNAs in gallbladder cancer. Int J Clin Exp Pathol 2014;7:1849.
Kim TH, Song JY, Park H, et al. miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma. Cancer Lett 2015;356(2 pt B):937–45.
Zhang W, Wang Q, Yu M, Wu N, Wang H. MicroRNA-145 function as a cell growth repressor by directly targeting c-Myc in human ovarian cancer. Technol Cancer Res Treat 2014;13:161–8.